Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 14, 2026 - P2 | N=30 | Recruiting | Sponsor: West China Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • IO biomarker • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Thyroid Gland Carcinoma
|